CHARACTERIZATION OF THE SUBTYPES OF MUSCARINIC RECEPTORS INVOLVED IN THE ELECTROPHYSIOLOGICAL RESPONSE OF THE LENS TO ACETYLCHOLINE

被引:0
|
作者
THOMAS, GR [1 ]
DUNCAN, G [1 ]
WILLIAMS, MR [1 ]
SANDERSON, J [1 ]
机构
[1] UNIV E ANGLIA,SCH BIOL SCI,NORWICH NR4 7TJ,NORFOLK,ENGLAND
关键词
D O I
暂无
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
引用
收藏
页码:P217 / P217
页数:1
相关论文
共 50 条
  • [41] Muscarinic acetylcholine receptors involved in the regulation of neural stem cell proliferation and differentiation in vitro
    Zhou, C
    Wen, ZX
    Shi, DM
    Xie, ZP
    CELL BIOLOGY INTERNATIONAL, 2004, 28 (01) : 63 - 67
  • [42] Non-selectivity of the monoclonal antibody M35 for subtypes of muscarinic acetylcholine receptors
    CarsiGabrenas, JM
    VanDerZee, EA
    Luiten, PGM
    Potter, LT
    BRAIN RESEARCH BULLETIN, 1997, 44 (01) : 25 - 31
  • [43] REGULATION OF MUSCARINIC ACETYLCHOLINE-RECEPTORS
    KLEIN, WL
    PROCEEDINGS OF THE WESTERN PHARMACOLOGY SOCIETY, 1980, 23 : 449 - 458
  • [44] BIOCHEMICAL STUDIES ON MUSCARINIC ACETYLCHOLINE RECEPTORS
    BIRDSALL, NJM
    HULME, EC
    JOURNAL OF NEUROCHEMISTRY, 1976, 27 (01) : 7 - 16
  • [45] SUBTYPE OF MUSCARINIC ACETYLCHOLINE-RECEPTORS
    UCHIDA, S
    JAPANESE JOURNAL OF PHARMACOLOGY, 1985, 39 : P31 - P31
  • [46] Structure and activation of muscarinic acetylcholine receptors
    Hulme, EC
    Lu, ZL
    Saldanha, JW
    Bee, MS
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2003, 31 : 29 - 34
  • [47] MUSCARINIC ACETYLCHOLINE RECEPTORS IN CAT IRIS
    KLOOG, Y
    SACHS, DI
    KORCZYN, AD
    HERON, DS
    SOKOLOVSKY, M
    BIOCHEMICAL PHARMACOLOGY, 1979, 28 (09) : 1505 - 1511
  • [48] FUNCTION OF MUSCARINIC AND NICOTINIC ACETYLCHOLINE RECEPTORS
    PURVES, RD
    NATURE, 1976, 261 (5556) : 149 - 151
  • [49] Molecular biology of muscarinic acetylcholine receptors
    Wess, J
    CRITICAL REVIEWS IN NEUROBIOLOGY, 1996, 10 (01): : 69 - 99
  • [50] Allosteric modulation of muscarinic acetylcholine receptors
    Tucek, S
    Dolezal, V
    Jakubík, J
    Krejcíi, A
    Lysíková, M
    5TH CONGRESS OF THE EUROPEAN SOCIETY FOR CLINICAL NEUROPHARMACOLOGY, 2000, : 117 - 123